Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Paul Mattels is an analyst at Stifel. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/28/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/16/2024 | DNLI | Buy Now | Denali Therapeutics | $14.20 | 160.56% | Paul Mattels7% | → $37 | Upgrade | Hold → Buy | Get Alert |
| 05/08/2024 | DNLI | Buy Now | Denali Therapeutics | $14.20 | 54.93% | Paul Mattels7% | $26 → $22 | Maintains | Hold | Get Alert |
| 02/19/2020 | ALEC | Buy Now | Alector | $1.33 | 3208.27% | Paul Mattels7% | → $44 | Initiates | → Buy | Get Alert |
| 02/19/2020 | DNLI | Buy Now | Denali Therapeutics | $14.20 | 83.1% | Paul Mattels7% | → $26 | Initiates | → Hold | Get Alert |
